Managing Inner City Asthma with Sublingual Immunotherapy: A Retrospective Chart Review
Monday, March 5, 2018
South Hall A2 (Convention Center)
Roberto Garcia-Ibanez, MD FAAAAI, Andrea Lucania, ARNP

A retrospective chart review has been conducted for 38 inner city asthmatics whose asthma and allergic rhinitis have been managed by sublingual immunotherapy (SLIT) and medication therapy for six months. Just as with traditional subcutaneous immunotherapy (SCIT), a three to five year course of treatment is recommended with SLIT to generate the most effective and lasting tolerance to allergens.


The inner city asthmatic population is difficult to manage on traditional SCIT as there is a high attrition rate in therapy due to: discontinuation/lapses of insurance coverage, lack of transportation, language barriers, lack of tolerance and noncompliance. By treating this population with SLIT, some of these factors are ameliorated as the patient has less frequent office visits and there is better tolerability than with traditional SCIT.


There was an average increase in FEV1 of 21% after six months of SLIT in 24 subjects. There was an average increase in ACT scores of 20% after six months of SLIT in 16 subjects. There was an average decrease in TSS of 28% after six months of SLIT in 36 subjects. 46% of patients had a decrease in asthma medication use after six months of SLIT in 38 subjects.


These results are encouraging and suggest that this modality of therapy should be seriously explored in the management of bronchial asthma in this population.